Invesco Biotechnology & Genome ETF PBE
Strategy
The investment seeks to track the investment results (before fees and expenses) of the Dynamic Biotech & Genome IntellidexSM Index. Under normal circumstances, at least 80% of the value of its net assets, plus the amount of any borrowings for investment purposes, in securities of companies engaged in biotechnology- and genome-related industries, and in derivatives and other investments that have economic characteristics similar to securities of companies engaged in biotechnology- and genome-related industries (the “80% investment policy”). It is non-diversified.
Ticker | Name | Share Class Type | Investment Status | Morningstar Rating for Funds Overall | Medalist Rating Overall | Inception Date | Total Net Assets for Share Class | Adjusted Expense Ratio | Fee Level Distribution | Minimum Initial Investment | 1-Year Net Flow |
|---|---|---|---|---|---|---|---|---|---|---|---|
PBE | Invesco Biotechnology & Genome ETF | ETF | Open | $425.03M | 0.590% | — | — | $109.92M |